Please assess the completion status of the following clinical trial:

Trial Title: Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-75 years~* Female patients must not be pregnant or breast-feeding~* Patients must be moderately overweight~* All patients must have abnormal cholesterol levels or a history of abnormal cholesterol levels as defined by the protocol.~* Patients taking medication to lower their cholesterol must be willing, in some cases, to discontinue their medications during the study Stable weight (a history of increasing or decreasing no more than 6.6 lbs \[3 kg\]) for at least 2 months prior to the study;~Exclusion Criteria~* Cancer or a history of a cancer within 5 years before screening, other than some skin cancers~* Patients planning elective surgery during the study~* Patients with a history of diabetes mellitus at study onset~* History of intolerance to, or adverse effect from atorvastatin~* History of weight loss due to stomach bypass or eating disorder~* All patients may not have had a stroke, TIA, an acute myocardial infarction, angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization) lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy) within 5 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Placebo (Type: PLACEBO_COMPARATOR): None
- MBX-8025 50 mg/Placebo (Type: EXPERIMENTAL): None
- MBX-8025 100 mg/Placebo (Type: EXPERIMENTAL): None
- Placebo/Atorvastatin 20 mg (Type: ACTIVE_COMPARATOR): None
- MBX-8025 50 mg/Atorvastatin 20 mg (Type: EXPERIMENTAL): None
- MBX-8025 100 mg/Atorvastatin 20 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).